Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Feb 11:16:17.
doi: 10.1186/s12903-016-0177-0.

The safety and efficacy of AphtoFix® mouth ulcer cream in the management of recurrent aphthous stomatitis

Amina Sakly  1   2 , Bart De Wever  3 , Balraj Jutla  4   5 , Milan Satia  6 , Jean Pierre Bogaert  7   8
Affiliations
Clinical Trial

The safety and efficacy of AphtoFix® mouth ulcer cream in the management of recurrent aphthous stomatitis

Amina Sakly et al. BMC Oral Health. .

Abstract

Background: Recurrent Aphthous stomatitis (RAS) is a prevalent ulcerative and painful disorder of the oral cavity with unknown etiology and for which no efficient treatment is currently available. The present study aimed to evaluate the safety and the efficacy of AphtoFix®, a new mouth ulcer cream that was developed to help treat RAS. Prior to launching the product on the market, two initial safety assessment studies were performed.

Subjects and methods: In a first study, the in vitro biocompatibility of AphtoFix® was evaluated on reconstructed human gingival tissue models according to ISO guidelines 10993. In a second study, the tolerability of AphtoFix® was evaluated in 20 subjects during a 4-weeks daily application in the mouth. The third study investigated both the safety and efficacy of AphtoFix® treatment on 19 patients suffering from RAS. This study was done in compliance with the Helsinki Declaration.

Results: The results of in vitro biocompatibility study showed that AphtoFix® mouth ulcer cream did not induce any detectable cytotoxicity and irritation. These observations were confirmed in the 4 weeks tolerability study where no undesired of adverse reactions were noticed. The results of the post-market clinical efficacy study demonstrated a clear reduction in ulcer size from baseline after 3 days treatment (p < 0.05). Pain intensity reduction was also observed in all subjects.

Conclusion: The application of AphtoFix® did not induce any undesired skin or mucosa reactions. These initial findings demonstrate that AphtoFix® is safe and efficient in reducing ulcer size and decreasing the pain intensity induced by ulcers.

Trial registration: Clinical trial Registry India Nr. CTRI201408004918 , Date of registration: 22/08/2014.

PubMed Disclaimer

References

    1. Porter SR, Scully C, Pedersen A. Recurrent aphthous stomatitis. Crit Rev Oral Biol Med. 1998;9:306–21. doi: 10.1177/10454411980090030401. - DOI - PubMed
    1. Chavan M, Jain H, Diwan N, Khedkar S, Shete A, Durkar S. Recurrent aphthous stomatitis: a review. J Oral Pathol Med. 2012;41:577–83. doi: 10.1111/j.1600-0714.2012.01134.x. - DOI - PubMed
    1. Preeti L, Magesh K, Rajkumar K, Karthik R. Recurrent aphthous stomatitis. J Oral Maxillofac Pathol. 2011;15:252–6. doi: 10.4103/0973-029X.86669. - DOI - PMC - PubMed
    1. Quijano D, Rodríguez M. Topical corticosteroids in recurrent aphthous stomatitis. Systematic review. Acta Otorrinolaringol Esp. 2008;59:298–307. doi: 10.1016/S0001-6519(08)73314-4. - DOI - PubMed
    1. Zhou Y, Chen Q, Meng W, Jiang L, Wang Z, Liu J, Lin M, Zhou H, Chen X, Zhao M, Zeng X. Evaluation of penicillin G potassium troches in the treatment of minor recurrent aphthous ulceration in a Chinese cohort: a randomized, double-blinded, placebo and no-treatment-controlled, multicenter clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109:561–6. - PubMed

Publication types

Associated data